DDInter556 DDInter1376
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Dihydrocodeine {u} (Compound) binds {v} (Gene) CYP2D6
Dihydrocodeine {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dihydrocodeine {u} (Compound) causes {v} (Side Effect) Somnolence
Dihydrocodeine (Compound) resembles Galantamine (Compound)
Dihydrocodeine (Compound) resembles Oxymorphone (Compound)
Dihydrocodeine (Compound) binds CYP2D6 (Gene)
Dihydrocodeine (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dihydrocodeine (Compound) causes Somnolence (Side Effect)